KYMR
NEUTRAL
$85.05
Live
Kymera Therapeutics, Inc. · NASDAQ
Target $119.14
(+40.1%)
$24.23
52W Range
$103.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$6.94B
P/E
N/A
ROE
-25.8%
Profit margin
N/A
Debt/Equity
0.05
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
75%
KYMR presents a dichotomy between a rock-solid balance sheet and deteriorating operational fundamentals. The company maintains a stable Piotroski F-Score of 6/9 and exceptional liquidity (Current Ratio 10.47), providing a significant cash runway for its biotech pipeline. However, this is countered by a severe revenue collapse of 61.2% YoY and a consistent failure to meet earnings estimates (0/4 beats in the last year). While analysts remain aggressively bullish with a 'Strong Buy' rating, the bearish insider sentiment and extreme Price/Sales ratio (177.09) suggest a high-risk speculative profile.
Key Strengths
Exceptional liquidity with a Current Ratio of 10.47
Minimal leverage with a Debt/Equity ratio of 0.05
Stable financial health as indicated by a Piotroski F-Score of 6/9
Strong historical price momentum (+279.7% over 1 year)
High analyst conviction with a target price of $119.14
Key Risks
Severe revenue contraction of -61.20% YoY
Consistent earnings misses with an average surprise of -22.16% over the last 4 quarters
Extreme valuation metrics, specifically a Price/Sales ratio of 177.09
Bearish insider activity with $19.55M in sales and zero buys
Negative forward P/E indicating continued losses
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
39
Weak
10
40
60
85
0
AI Verdict
Speculative / High Risk
Key drivers: Strong balance sheet/cash runway, Severe revenue decline, Extreme P/S valuation, Divergence between analysts and insiders
Confidence
80%
Value
10/100
Stock trades at a massive premium based on future pipeline expectations rather than current fundamentals.
Positives
No standout positives identified.
Watchpoints
- P/S ratio of 177.09 is astronomical
- Negative Forward P/E
- No Graham Number available due to lack of earnings
Future
40/100
Future success is entirely dependent on clinical catalysts, as current growth metrics are crashing.
Positives
- Strong analyst target price ($119.14)
Watchpoints
- Negative YoY and Q/Q revenue growth
- Poor earnings surprise track record
Past
60/100
Price performance has been decoupled from fundamental earnings performance.
Positives
- Exceptional 1Y, 3Y, and 5Y price returns
Watchpoints
- Long history of missing earnings estimates
Health
85/100
Financial health is the company's strongest attribute, ensuring survival despite losses.
Positives
- Piotroski F-Score of 6/9
- Very low Debt/Equity (0.05)
- High Current and Quick Ratios (>10)
Watchpoints
No urgent risks highlighted.
Dividend
0/100
Standard for early-to-mid stage biotechnology firms.
Positives
No standout positives identified.
Watchpoints
- No dividend yield
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$85.05
Analyst Target
$119.14
Upside/Downside
+40.1%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for KYMR and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
Primary
|
+170.6% | +171.2% | +279.7% | +48.7% | +4.3% | -0.4% |
|
MOH
Molina Healthcare, Inc.
Peer
|
-42.2% | -50.0% | -58.5% | -29.4% | -10.7% | -2.7% |
|
GRFS
Grifols, S.A.
Peer
|
-51.1% | +11.6% | +28.0% | -11.9% | +2.2% | -0.4% |
|
ACLX
Arcellx, Inc.
Peer
|
+580.9% | +279.9% | +59.8% | +50.1% | +63.7% | +0.1% |
|
HQY
HealthEquity, Inc.
Peer
|
+11.9% | +34.2% | -2.5% | -13.9% | -0.8% | -7.9% |
KYM
Kymera Therapeutics, Inc.
Primary
5Y
+170.6%
3Y
+171.2%
1Y
+279.7%
6M
+48.7%
1M
+4.3%
1W
-0.4%
MOH
Molina Healthcare, Inc.
Peer
5Y
-42.2%
3Y
-50.0%
1Y
-58.5%
6M
-29.4%
1M
-10.7%
1W
-2.7%
GRF
Grifols, S.A.
Peer
5Y
-51.1%
3Y
+11.6%
1Y
+28.0%
6M
-11.9%
1M
+2.2%
1W
-0.4%
ACL
Arcellx, Inc.
Peer
5Y
+580.9%
3Y
+279.9%
1Y
+59.8%
6M
+50.1%
1M
+63.7%
1W
+0.1%
HQY
HealthEquity, Inc.
Peer
5Y
+11.9%
3Y
+34.2%
1Y
-2.5%
6M
-13.9%
1M
-0.8%
1W
-7.9%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-21.22
PEG Ratio
N/A
P/B Ratio
4.38
P/S Ratio
177.09
EV/Revenue
157.55
EV/EBITDA
-18.23
Market Cap
$6.94B
Profitability
Profit margins and return metrics
Profit Margin
N/A
Operating Margin
-3411.01%
Gross Margin
N/A
ROE
-25.78%
ROA
-15.88%
Growth
Revenue and earnings growth rates
Revenue Growth
-61.2%
Earnings Growth
N/A
Q/Q Revenue Growth
-61.18%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.05
Low debt
Current Ratio
10.47
Strong
Quick Ratio
10.19
Excellent
Cash/Share
$10.39
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.0B
Op. Margin
-3411.0%
Net Margin
-3030.7%
Total Assets
$1.7B
Liabilities
$0.2B
Equity
$1.6B
Debt/Equity
0.10x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
100%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-08
$N/A
2026-02-26
$-0.98
-27.1% surprise
2025-11-04
$-0.94
-20.3% surprise
2025-08-11
$-0.95
-19.1% surprise
Healthcare Sector Comparison
Comparing KYMR against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
Return on Equity (ROE)
-25.78%
This Stock
vs
-49.88%
Sector Avg
-48.3%
(Below Avg)
Debt to Equity
0.05
This Stock
vs
3.74
Sector Avg
-98.6%
(Less Debt)
Revenue Growth
-61.2%
This Stock
vs
80.78%
Sector Avg
-175.8%
(Slower)
Current Ratio
10.47
This Stock
vs
3.72
Sector Avg
+181.5%
(Stronger)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
KYMR
Kymera Therapeutics, Inc.
|
NEUTRAL | $6.94B | - | -25.8% | -% | $85.05 | |
|
MOH
Molina Healthcare, Inc.
|
NEUTRAL | $7.09B | 15.25 | 11.0% | 1.1% | $136.03 | Compare |
|
GRFS
Grifols, S.A.
|
NEUTRAL | $6.74B | 12.83 | 6.2% | 5.3% | $8.21 | Compare |
|
ACLX
Arcellx, Inc.
|
BEARISH | $6.69B | - | -53.4% | -% | $114.39 | Compare |
|
HQY
HealthEquity, Inc.
|
NEUTRAL | $6.66B | 31.69 | 10.2% | 16.4% | $77.96 | Compare |
KYMR
Kymera Therapeutics, Inc.
NEUTRAL
Mkt Cap
$6.9B
P/E
-
ROE
-25.8%
Price
$85.05
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | CHADWICK JEREMY G | Chief Operating Officer | Sale | 22,240 | $1,900,048 |
| 2026-04-01 | CHADWICK JEREMY G | Chief Operating Officer | Option Exercise | 22,240 | $659,194 |
| 2026-04-01 | RIDLOFF ELENA | Director | Sale | 12,000 | $1,024,660 |
| 2026-04-01 | RIDLOFF ELENA | Director | Option Exercise | 12,000 | $170,160 |
| 2026-03-25 | CHADWICK JEREMY G | Chief Operating Officer | Sale | 115,977 | $9,048,290 |
| 2026-03-25 | CHADWICK JEREMY G | Chief Operating Officer | Option Exercise | 109,127 | $3,234,524 |
| 2026-03-20 | ESPOSITO PAMELA | Director | Sale | 2,500 | $197,877 |
| 2026-03-20 | ESPOSITO PAMELA | Director | Option Exercise | 2,500 | $122,750 |
| 2026-03-11 | CHADWICK JEREMY G | Chief Operating Officer | Sale | 25,758 | $2,145,673 |
| 2026-03-11 | CHADWICK JEREMY G | Chief Operating Officer | Option Exercise | 20,000 | $870,000 |
| 2026-03-04 | CHADWICK JEREMY G | Chief Operating Officer | Sale | 5,958 | $515,594 |
| 2026-03-04 | GOLLOB JARED AUGUST | Officer | Sale | 10,508 | $916,669 |
| 2026-03-04 | JACOBS BRUCE N. | Chief Financial Officer | Sale | 12,471 | $1,091,231 |
| 2026-03-02 | CHADWICK JEREMY G | Chief Operating Officer | Stock Award | 12,575 | - |
| 2026-03-02 | ADAMS BRIAN R | Officer | Stock Award | 4,125 | - |
CHADWICK JEREMY G
Chief Operating Officer
2026-04-01
22,240 shares
·
$1,900,048
CHADWICK JEREMY G
Chief Operating Officer
2026-04-01
22,240 shares
·
$659,194
RIDLOFF ELENA
Director
2026-04-01
12,000 shares
·
$1,024,660
RIDLOFF ELENA
Director
2026-04-01
12,000 shares
·
$170,160
CHADWICK JEREMY G
Chief Operating Officer
2026-03-25
115,977 shares
·
$9,048,290
CHADWICK JEREMY G
Chief Operating Officer
2026-03-25
109,127 shares
·
$3,234,524
ESPOSITO PAMELA
Director
2026-03-20
2,500 shares
·
$197,877
ESPOSITO PAMELA
Director
2026-03-20
2,500 shares
·
$122,750
CHADWICK JEREMY G
Chief Operating Officer
2026-03-11
25,758 shares
·
$2,145,673
CHADWICK JEREMY G
Chief Operating Officer
2026-03-11
20,000 shares
·
$870,000
CHADWICK JEREMY G
Chief Operating Officer
2026-03-04
5,958 shares
·
$515,594
GOLLOB JARED AUGUST
Officer
2026-03-04
10,508 shares
·
$916,669
JACOBS BRUCE N.
Chief Financial Officer
2026-03-04
12,471 shares
·
$1,091,231
CHADWICK JEREMY G
Chief Operating Officer
2026-03-02
12,575 shares
ADAMS BRIAN R
Officer
2026-03-02
4,125 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
21 analysts
UBS
2026-03-03
Buy
Buy
Citigroup
2026-03-02
Buy
Buy
Stephens & Co.
2026-03-02
Overweight
Overweight
BTIG
2026-02-26
Buy
Buy
Piper Sandler
2026-02-26
Overweight
Overweight
BTIG
2026-02-03
Buy
Buy
Barclays
2026-01-28
Overweight
Overweight
BTIG
2026-01-15
Buy
Buy
Wolfe Research
2026-01-06
Outperform
Peer Perform
B. Riley Securities
2025-12-22
Buy
Buy
Past News Coverage
Recent headlines mentioning KYMR from our newsroom.
Newest → oldest
No matching news yet.